Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Asparaginase Enzyme Activity Levels and Toxicity in Childhood Acute Lymphoblastic Leukemia: a NOPHO ALL2008 study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pancreatitis-associated protein as an early marker of asparaginase-associated pancreatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Health care utilisation following childhood acute lymphoblastic leukaemia: a population-based matched cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Increments in DNA-thioguanine level during thiopurine enhanced maintenance therapy of acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Asparaginase treatment is a mainstay in contemporary treatment of acute lymphoblastic leukemia (ALL), but substantial asparaginase-related toxicity may lead to jeopardized protocol compliance and compromises survival. We investigated the association between risk of asparaginase-associated toxicities (AspTox) and asparaginase enzyme activity (AEA) levels in 1155 children aged 1.0 to 17.9 years, diagnosed with ALL between July 2008 and March 2016, and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol. Patients with ≥2 blood samples for AEA measurement drawn 14 ± 2 days after asparaginase administration were included (6944 trough values). AEA was measurable (or >0 IU/L) in 955 patients, whereas 200 patients (17.3%) had asparaginase inactivation and few AspTox recorded. A time-dependent multiple Cox model of time to any first asparaginase-associated toxicity adjusted for sex and age was used. For patients with measurable AEA, we found a hazard ratio (HR) of 1.17 per 100 IU/L increase in median AEA (95% confidence interval [CI], 0.98-1.41; P = .09). For pancreatitis, thromboembolism, and osteonecrosis, the HRs were 1.40 (95% CI, 1.12-1.75; P = .002), 0.99 (95% CI, 0.70-1.40; P = .96), and 1.36 (95% CI, 1.04-1.77; P = .02) per 100 IU/L increase in median AEA, respectively. No significant decrease in the risk of leukemic relapse was found: HR 0.88 per 100 IU/L increase in AEA (95% CI, 0.66-1.16; P = .35). In conclusion, these results emphasize that overall AspTox and relapse are not associated with AEA levels, yet the risk of pancreatitis and osteonecrosis increases with increasing AEA levels.

Original languageEnglish
JournalBlood advances
Volume6
Issue number1
Pages (from-to)138-147
Number of pages10
ISSN2473-9529
DOIs
Publication statusPublished - 11 Jan 2022

Bibliographical note

Copyright © 2021 American Society of Hematology.

ID: 68508687